Losec 20 mg

/ Abic

Acute Duodenal Ulcer: The recommended dosage is 20 mg once daily. Symptom resolution is rapid and in most patients healing occurs within 4 weeks. For those patients who may not have fully healed after the initial course, healing usually occurs during a further 4 weeks treatment period.
In patients with poorly responsive duodenal ulcer, Losec 40 mg once daily is recommended and healing is usually achieved within 4 weeks.
The effectiveness of Losec is not affected by concomitant NSAID treatment and the usual duration of treatment is recommended.
Acute Gastric Ulcer: The recommended dosage is 20 mg once daily. Symptom resolution is rapid and in most patients healing occurs within 4 weeks. For those patients who may not have fully healed after the initial course, healing usually occurs during a further 4 weeks treatment period.
In patients with poorly responsive gastric ulcer, 40 mg Losec once daily has been used and healing is usually achieved within 8 weeks.
The effectiveness of Losec is not affected by concomitant NSAID treatment and the usual duration of treatment is recommended.
Use in the Elderly: No dosage adjustment is necessary in the elderly.
Use in Patients with Impaired Hepatic Function: As bioavailability and half-life can increase in patients with impaired hepatic function, the dose requires adjustment with a maximum daily dose of 20 mg.
Use in Patients with Impaired Renal Function: Dose adjustment is not required in patients with impaired renal function.
Method of administration: It is recommended to take Losec capsules in the morning, preferably without food, swallowed whole with half a glass of water. The capsules must not be chewed or crushed.
See prescribing information for full details.

Acute duodenal ulcer. Acute gastric ulcer. H. pylori-associated peptic ulcer disease in combination with antibiotics. Reflux esophagitis: Treatment, long-term management, maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. Treatment of severe reflux esophagitis in children from one year of age and older. Maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer. Zollinger-Ellison syndrome. Treatment and prevention of NSAID-associated duodenal and gastric ulcers or erosions in high risk patients.

Known hypersensitivity to any ingredient of the product. Children and adolescents under 18 years of age. Patients suffering from pain while swallowing food, vomiting with blood, bloody or black stools. Combination with atazanavir.

Pregnancy and lactation, pediatrics, hepatic disease.

Rash, urticaria, pruritus, arthralgia, muscular weakness, myalgia, headache, dizziness, paresthesia, somnolence, insomnia, vertigo, diarrhea, constipation, abdominal pain, nausea/flatulence.

Ketoconazole, itraconazole, diazepam, phenyltoin, warfarin. See literature.